Katsanevakis Emmanouil, Oatham Alice, Mathew Darly
Obstetrics and Gynaecology, United Lincolnshire Hospitals National Health Service Trust, Lincoln, GBR.
Obstetrics and Gynaecology, Chesterfield Royal Hospital, Chesterfield, GBR.
Cureus. 2022 Feb 14;14(2):e22200. doi: 10.7759/cureus.22200. eCollection 2022 Feb.
Choriocarcinoma is a disease associated with uncontrollable proliferation and malignant change of cells of the placenta and belongs to the malignant end of the spectrum in gestational trophoblastic disease. These tumours are usually developed after molar pregnancies, and their incidence after full-term pregnancies is extremely rare. We present a very rare case of a 30-year-old lady, admitted with a five-month history of vaginal bleeding after a normal pregnancy. The human chorionic gonadotropin (hCG) was at a level of 209,566. A pelvic ultrasound scan revealed an endometrial thickness of 6 cm and the presence of an intra-uterine mass measuring 56 × 50 × 45 mm. After discussion with the regional gestational trophoblastic disease centre, we proceeded to a surgical evacuation of the uterus, which confirmed a post-partum choriocarcinoma (International Federation of Gynaecology and Obstetrics (FIGO) score 9). Care was continued in the specialised centre with multi-agent chemotherapy. The response was excellent, and the patient was subsequently discharged after 10 cycles of chemotherapy, and a 10-year follow-up was arranged. Choriocarcinomas after full-term pregnancies are a rare entity. Even when they happen, they are usually associated with pregnancy complications in the ante-natal period. The prognosis is usually very good, provided that prompt diagnosis and referral to a specialised centre are made. Low-risk patients are usually treated with methotrexate monotherapy, whereas high-risk women would normally require multi-agent chemotherapy. The diagnosis of choriocarcinoma might be proven challenging even for experienced clinicians. Women should be informed that the prognosis is usually excellent, provided that they receive the right treatment.
绒毛膜癌是一种与胎盘细胞不受控制的增殖和恶性变化相关的疾病,属于妊娠滋养细胞疾病谱系中的恶性终端。这些肿瘤通常在葡萄胎妊娠后发生,足月妊娠后其发病率极为罕见。我们报告一例非常罕见的病例,一名30岁女性,因正常妊娠后出现五个月的阴道出血入院。人绒毛膜促性腺激素(hCG)水平为209,566。盆腔超声扫描显示子宫内膜厚度为6厘米,子宫内有一个大小为56×50×45毫米的肿块。与地区妊娠滋养细胞疾病中心讨论后,我们进行了子宫手术排空,证实为产后绒毛膜癌(国际妇产科联合会(FIGO)评分9分)。在专科中心继续进行多药化疗。反应良好,患者在化疗10个周期后出院,并安排了10年随访。足月妊娠后的绒毛膜癌是一种罕见的疾病。即使发生,通常也与产前的妊娠并发症有关。如果能及时诊断并转诊至专科中心,预后通常非常好。低风险患者通常采用甲氨蝶呤单药治疗,而高风险女性通常需要多药化疗。即使对于经验丰富的临床医生来说,绒毛膜癌的诊断也可能具有挑战性。应告知女性,只要接受正确的治疗,预后通常非常好。